Welcome to our dedicated page for Corvel SEC filings (Ticker: CRVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how CorVel Corporation converts advanced analytics into lower claim costs is vital, yet the company’s SEC paperwork is a maze of healthcare billing codes, captive insurance structures, and network contracting jargon. If you have ever searched “What does CorVel report in its 10-K?” or tried to locate a single footnote on network revenue in a 300-page filing, you know the challenge. Stock Titan resolves that frustration by layering AI-driven language models on top of every disclosure, turning raw documents into plain-English takeaways you can scan in seconds.
Open the CorVel annual report 10-K simplified to see segment profitability, risk factors, and how the CareMC platform scales. Need the latest CorVel quarterly earnings report 10-Q filing? We post it within minutes of hitting EDGAR and attach side-by-side KPI trends. Material updates, such as new managed-care contracts or Medicare set-aside rulings, appear under CorVel 8-K material events explained. Our dashboard also streams CorVel insider trading Form 4 transactions and CorVel executive stock transactions Form 4 so you can watch ownership shifts in real time and cross-check details in the CorVel proxy statement executive compensation section.
Whether you’re benchmarking medical cost containment peers or simply want CorVel SEC filings explained simply, Stock Titan’s tools help you:
- Spot margin shifts with CorVel earnings report filing analysis.
- Receive CorVel Form 4 insider transactions real-time on any device.
- Compare claim volume trends across regions without reading every exhibit.
- Understand complex reimbursement tables with AI-powered summaries.
All filings update automatically, and every paragraph links back to the source so analysts, insurers, and portfolio managers can trust the detail while saving hours. Understanding CorVel SEC documents with AI no longer requires a legal background—just open the page and let the insights surface.
Brandon O'Brien, Chief Financial Officer and Director of CorVel Corp (CRVL), reported agift disposition of 1,120 shares on 08/27/2025. The Form 4 shows the transaction coded G(1) with a price of $0.0 and an explanation stating the shares were gifted to "O'Brien Family Fund - DAFgiving360." After the reported disposition, Mr. O'Brien beneficially owned 10,712 shares. The filing lists the reporting persons address in Fort Worth, TX, and the Form is signed/submitted on 08/28/2025 by Sharon OConnor on behalf of Brandon OBrien.
Brandon O'Brien, Chief Financial Officer of CorVel Corp (CRVL), reported option exercise and related share transactions dated 08/22/2025. He exercised a non-qualified stock option to acquire 1,200 shares at an exercise price of $49.63, resulting in ownership of 1,200 underlying shares from that option. Concurrently, two sale transactions (codes F) show dispositions of 658 shares at $90.45 and 514 shares at $92.64. Following the reported transactions his reported beneficial ownership changed from 13,004 to 11,832 shares. The filing notes some shares were delivered to satisfy the option exercise price and/or tax liability and that the option vests 25% after one year with the remainder vesting monthly over three years.
Maxim Shishin, Chief Information Officer of CorVel Corp (CRVL), reported option exercise and share sale transactions on 08/20/2025. He exercised 12,000 non-qualified stock options with an exercise price of $29.23 that are exercisable by 11/05/2025, resulting in ownership of 12,000 underlying shares from that exercise. On the same date he sold 12,000 shares at $89.1647 per share. After these transactions, his reported beneficial ownership in common stock was 7,050 shares and he beneficially owned 18,000 non-qualified stock options. The option vesting is tied to performance criteria related to earnings growth, per the filer.
Form 144 notice for CorVel Corporation (CRVL): An insider has notified intent to sell 12,000 shares of Common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate aggregate market value of $1,069,975.20 based on the filing. The filing reports 51,312,748 shares outstanding for the issuer.
The filing shows the 12,000 shares were acquired on 08/20/2025 via stock option exercise and payment was made in cash on 08/20/2025. The filer also sold 2,400 shares on 06/09/2025 for gross proceeds of $259,416.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Mark E. Bertels, EVP - Risk Management Services at CorVel Corporation (CRVL), reported same-day option exercise and a sale on 08/19/2025. He acquired 900 shares by exercising non-qualified stock options at an exercise price of $29.23 per share and simultaneously sold 900 shares at $89.1678 per share. The option underlying 900 shares is exercisable and expires 11/05/2025; the award vests 25% after one year with the remainder in 36 monthly installments.
Following these transactions the filing shows beneficial ownership figures of 3,486 shares after the acquisition and 2,586 shares after the sale, indicating his reported stake ended at 2,586 shares. All amounts and dates are taken directly from the Form 4 filing.
CorVel Corporation (CRVL) insider disclosure shows a proposed sale of 900 common shares through Morgan Stanley Smith Barney on 08/19/2025 with an aggregate market value of $80,251.02. The filer reports acquiring the 900 shares via a stock option exercise on 08/19/2025 and paying in cash. The filing also lists a prior sale of 900 shares by the same person on 05/27/2025 that generated $102,002.58 in gross proceeds. The company has 51,312,748 shares outstanding, so the proposed sale represents a de minimis fraction of total shares. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.
CorVel Corporation held its 2025 Annual Meeting of Stockholders on August 7, 2025. At the record date there were 51,440,930 shares outstanding. Six director nominees were elected to serve until 2026, with individual "For" votes ranging from 40,028,742 to 47,158,201 and broker non-votes of 1,630,174 reported for each director.
Shareholders also ratified the appointment of Haskell & White LLP as the independent registered public accounting firm by a vote of 48,879,993 For, 149,755 Against and 11,900 Abstain. The company’s 2025 Stock Incentive Plan was approved with 39,814,198 For, 7,566,390 Against, 30,886 Abstain and 1,630,174 broker non-votes.
Michael Jeffrey J, identified as a director and 10% owner of CorVel Corp (CRVL), was granted 1,500 non-qualified stock options on 08/07/2025 with an exercise price of $85.56. The options expire on 08/07/2035 and become exercisable in four equal annual installments beginning 12 months after the grant, so vesting begins on 08/07/2026. The Form 4 reports the reporting person directly beneficially owns 1,500 derivative securities following the transaction. The filing is signed on 08/11/2025.
CorVel Corp. (CRVL) director Jessup R. Judd was granted 1,500 non-qualified stock options on 08/07/2025 with an exercise price of $85.56. The award represents the right to acquire 1,500 shares of common stock and is reported as direct beneficial ownership.
The options vest in four equal annual installments beginning 12 months after the grant (first vesting about 08/07/2026) and expire on 08/07/2035. The Form 4 records the acquisition (code A) of these derivative securities and shows 1,500 derivative securities owned following the transaction.
Steven Hamerslag, a director of CorVel Corp (CRVL), was granted a non-qualified stock option to purchase 1,500 shares at an exercise price of $85.56. The option is exercisable in four equal annual installments beginning 12 months after the grant date and expires on 08/07/2035.
Following the reported transaction the filing shows beneficial ownership of 1,500 shares on a direct basis. The filing records the grant terms and the vesting schedule but does not disclose total dilution, percentage ownership, or any cash proceeds received.